Tumor‐promoting activities of TGF‐β within the TME, which include EMT, fibrosis, angiogenesis, and immunosuppression, are nonredundant with the tumor‐evasive mechanisms mediated by PD‐L1; hence, simultaneous inhibition of TGF‐β and PD‐L1 pathways may allow for increased overall efficacy compared with independent blockade of either pathway alone. This evidence concerns the gene TGFB1 and neoplasm.